4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase

Journal of Nutritional Biochemistry

Volumn 22, Issue 5, 2011, Pages 476-486

  Lee, Yong Kyung ^a   Choi, Im Seop ^a   Ban, Jung Ok ^a   Lee, Hwa Jeong ^a   Lee, Ung Soo ^b   Han, Sang Bae ^a   Jung, Jae Kyung ^a   Kim, Young Hee ^c   Kim, Ki Ho ^c   Oh, Ki Wan ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Chungju National University   (South Korea)

^c Bioland Ltd   (South Korea)

Author keywords

amyloid; 4 O MH; Alzheimer's disease; P38 MAP kinase

Indexed keywords

4 O METHYLHONOKIOL; AMYLOID BETA PROTEIN; GLUTATHIONE; HONOKIOL; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INACTIVATION; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOUSE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; ASTROCYTES; BIPHENYL COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LIGNANS; LIPID PEROXIDATION; MAGNOLIA; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEURONS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PROTEIN CARBONYLATION; REACTIVE OXYGEN SPECIES;

MAGNOLIA OFFICINALIS; MUS;

EID: 79954592028     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.04.002     Document Type: Article

References (63)

1. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48(4):567-579.
2. Joachim C.L., Selkoe D.J. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord 1992, 6(1):7-34.
3. Cerpa W., Dinamarca M.C., Inestrosa N.C. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008, 5(3):233-243.
4. Selkoe D.J. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(20):11039-11041.
5. Maccioni M., Riera C.M., Rivero V.E. Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor. J Reprod Immunol 2001, 50(2):133-149.
6. Lecanu L., Yao W., Teper G.L., Yao Z.X., Greeson J., Papadopoulos V. Identification of naturally occurring spirostenols preventing beta-amyloid-induced neurotoxicity. Steroids 2004, 69(1):1-16.
7. Hwang D.Y., Chae K.R., Kang T.S., Hwang J.H., Lim C.H., Kang H.K., et al. Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 2002, 16:805-813.
8. Lee S.Y., Hwang D.Y., Kim Y.K., Lee J.W., Shin I.C., Oh K.W., et al. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J 2006, 20:151-153.
9. Feld M., Galli C., Piccini A., Romano A. Effect on memory of acute administration of naturally secreted fibrils and synthetic amyloid-beta peptides in an invertebrate model. Neurobiol Learn Mem 2008, 89(4):407-418.
10. Repici M., Zanjani H.S., Gautheron V., Borsello T., Dusart I., Mariani J. Specific JNK inhibition by D-JNKI1 protects Purkinje cells from cell death in Lurcher mutant mouse. Cerebellum 2008, 7(4):534-538.
11. Chen H.S., He X., Qu F., Kang S.M., Yu Y., Liao D., et al. Differential roles of peripheral mitogen-activated protein kinase signal transduction pathways in bee venom-induced nociception and inflammation in conscious rats. J Pain 2009, 10(2):201-207.
12. Munoz L., Ranaivo H.R., Roy S.M., Hu W., Craft J.M., McNamara L.K., et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007, 4:21.
13. Zhu Y., Hou H., Nikolic W.V., Ehrhart J., Rrapo E., Bickford P., et al. CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation. PLoS One 2008, 3(5):e2135.
14. Origlia N., Righi M., Capsoni S., Cattaneo A., Fang F., Stern D.M., et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 2008 Mar 26, 28(13):3521-3530.
15. Song Y.S., Park H.J., Kim S.Y., Lee S.H., Yoo H.S., Lee H.S., et al. Protective role of Bcl-2 on beta-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-kappaB and p38 MAP kinase activation. Neurosci Res 2004, 49(1):69-80.
16. Lee J.W., Lee Y.K., Ban J.O., Ha T.Y., Yun Y.P., Han S.B., et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 2009, 139(10):1987-1993.
17. Lee S.Y., Lee J.W., Lee H.S., Yoo H.S., Yun Y.P., Oh K.W., et al. Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Mol Brain Res 2005, 140:45-54.
18. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res. 2002, 36(12):1307-1313.
19. Jang J.H., Surh Y.J. beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad Sci 2002, 973:228-236.
20. Dumont M., Wille E., Stack C., Calingasan N.Y., Beal M.F., Lin M.T. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 2009, 23(8):2459-2466.
21. Montiel T., Camacho A., Estrada-Sánchez A.M., Massieu L. Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (PDC) and the non-substrate inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo. Neuroscience 2005, 133(3):667-678.
22. Arias C., Montiel T., Quiroz-Báez R., Massieu L. beta-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Exp Neurol 2002, 176(1):163-174.
23. Yatin S.M., Varadarajan S., Butterfield D.A. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2000, 2(2):123-131.
24. Liou K.T., Shen Y.C., Chen C.F., Tsao C.M., Tsai S.K. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res 2003, 992(2):159-166.
25. Lin Y.R., Chen H.H., Ko C.H., Chan M.H. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 2006, 537(1-3):64-69.
26. Frank B., Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005, 17(4):269-286.
27. Rezai-Zadeh K., Arendash G.W., Hou H., Fernandez F., Jensen M., Runfeldt M., et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008, 1214:177-187.
28. Kim T.I., Lee Y.K., Park S.G., Choi I.S., Ban J.O., Park H.K., et al. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009, 47:1601-1610.
29. Kuribara H., Stavinoha W.B., Maruyama Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. J Pharm Pharmacol 1998, 50(7):819-826.
30. Watanabe K., Watanabe H., Goto Y., Yamaguchi M., Yamamoto N., Hagino K. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med 1983, 49(2):103-108.
31. Zhou H.Y., Shin E.M., Guo L.Y., Youn U.J., Bae K., Kang S.S., et al. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol 2008, 586(1-3):340-349.
32. Munroe M.E., Arbiser J.L., Bishop G.A. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 2007, 179(2):753-763.
33. Lin Y.R., Chen H.H., Ko C.H., Chan M.H. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007, 81(13):1071-1078.
34. Fujita S., Taira J. Biphenyl compounds are hydroxyl radical scavengers: their effective inhibition for UV-induced mutation in Salmonella typhimurium TA102. Free Radic Biol Med 1994, 17(3):273-277.
35. Dikalov S., Losik T., Arbiser J.L. Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol 2008, 76(5):589-596.
36. Chen C.L., Chang P.L., Lee S.S., Peng F.C., Kuo C.H., Chang H.T. Analysis of magnolol and honokiol in biological fluids by capillary zone electrophoresis. J Chromatogr A 2007, 1142(2):240-244.
37. Oh J.H., Kang L.L., Ban J.O., Kim Y.H., Kim K.H., Han S.B., et al. Anti-inflammatory effect of 4-O-MH, a novel compound isolated from Magnolia officinalis through inhibition of NF-kappaB. Chem Biol Interact 2009, 180(3):506-514.
38. Lee Y.K., Choi I.S., Kim Y.H., Kim K.H., Nam S.Y., Yun Y.W., et al. Neurite outgrowth effect of 4-O-MH by induction of neurotrophic factors through ERK activation. Neurochem Res 2009, 34:2251-2260.
39. Lee Y.K., Yuk D.Y., Kim T.I., Kim Y.H., Kim K.T., Kim K.H., et al. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-MH on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. Nat Med (Tokyo) 2009, 63(3):274-282.
40. Nabeshima T., Nitta A. Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats. Tohoku J Exp Med 1994, 174(3):241-249.
41. Frautschy S.A., Hu W., Kim P., Miller S.A., Chu T., Harris-White M.E., et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001, 22(6):993-1005.
42. Morris R. Developments of water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
43. Gibson G.E., Zhang H. Abnormalities in oxidative processes in non-neuronal tissues from patients with Alzheimer's disease. J Alzheimers Dis 2001, 3(3):329-338.
44. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408(6809):239-247.
45. Chiu J.H., Ho C.T., Wei Y.H., Lui W.Y., Hong C.Y. In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury. Life Sci 1997, 61(19):1961-1971.
46. Ou H.C., Chou F.P., Lin T.M., Yang C.H., Sheu W.H. Protective effects of honokiol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Chem Biol Interact 2006, 161(1):1-13.
47. Ou H.C., Chou F.P., Sheu W.H., Hsu S.L., Lee W.J. Protective effects of magnolol against oxidized LDL-induced apoptosis in endothelial cells. Arch Toxicol 2007, 81(6):421-432.
48. Drouet B., Pinçon-Raymond M., Chambaz J., Pillot T. Molecular basis of Alzheimer's disease. Cell Mol Life Sci. 2000, 57(5):705-715.
49. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16(5):921-932.
50. Harkany T., Abrahám I., Kónya C., Nyakas C., Zarándi M., Penke B., et al. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 2000, 11(4):329-382. [Review].
51. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77(6):817-827.
52. Yatin S.M., Aksenova M., Aksenov M., Markesbery W.R., Aulick T., Butterfield D.A. Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J Mol Neurosci 1998, 11(3):183-197.
53. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
54. Wasilewska-Sampaio A.P., Silveira M.S., Holub O., Goecking R., Gomes F.C., Neto V.M., et al. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. FASEB J 2005, 19(12):1627-1636.
55. Marques C.A., Keil U., Bonert A., Steiner B., Haass C., Muller W.E., et al. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J Biol Chem 2003, 278(30):28294-28302.
56. Ekinci F.J., Malik K.U., Shea T.B. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J Biol Chem 1999, 274(42):30322-30327.
57. Choi M.S., Lee S.H., Cho H.S., Kim Y., Yun Y.P., Jung H.Y., et al. Inhibitory effect of obovatol on nitric oxide production and activation of NF-kappaB/MAP kinases in lipopolysaccharide-treated RAW 264.7cells. Eur J Pharmacol 2007, 556(1-3):181-189.
58. Zhai H., Nakade K., Oda M., Mitsumoto Y., Akagi M., Sakurai J., et al. Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur J Pharmacol 2005, 516(2):112-117.
59. Tsai T.H., Chou C.J., Chen C.F. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 1996, 48(1):57-59.
60. Lin Y.L., Chen H.H., Ko C.H., Chan M.H. Differential inhibitory effect of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. J Neuropharm 2005, 542:550-558.
61. Cui H.S., Huang L.S., Sok D.E., Shin J., Kwon B.M., Youn U.J., et al. Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA. (1-100 mg/kg 3days). Phytomedicine 2007, 14(10):696-700.
62. Maruyama Y., Kuribara H., Kishi E., Weintraub S.T., Ito Y. Confirmation of the anxiolytic-like effect of dihydrohonokiol following behavioural and biochemical assessments. J Pharm Pharmacol 2001, 53(5):721-725.
63. Liu Z., Zhang X., Cui W., Zhang X., Li N., Chen J., et al. Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats. Regul Toxicol Pharmacol 2007, 49(3):160-171.